Activating the STING1 pathway is a promising strategy for cancer immunotherapy (Hines et al., 2023; Samson and Ablasser, 2022; Liu et al., 2021; Zheng et al., 2020; Corrales et al., 2015; Fu et al., 2015; Barber, 2011). This evidence concerns the gene STING1 and cancer.